A detailed history of Arrowstreet Capital, Limited Partnership transactions in Novo Nordisk A S stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 450,803 shares of NVO stock, worth $39.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
450,803
Previous 395,898 13.87%
Holding current value
$39.4 Million
Previous $56.5 Million 5.01%
% of portfolio
0.04%
Previous 0.05%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$119.07 - $145.42 $6.54 Million - $7.98 Million
54,905 Added 13.87%
450,803 $53.7 Million
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $48.6 Million - $58.2 Million
395,898 New
395,898 $56.5 Million
Q4 2023

Feb 14, 2024

SELL
$87.78 - $105.45 $59.9 Million - $72 Million
-682,356 Reduced 53.17%
601,007 $62.2 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $88.4 Million - $194 Million
972,122 Added 312.34%
1,283,363 $117 Million
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $33.4 Million - $37 Million
214,030 Added 220.17%
311,241 $50.4 Million
Q1 2023

May 15, 2023

BUY
$132.34 - $159.14 $11.4 Million - $13.8 Million
86,491 Added 806.82%
97,211 $15.5 Million
Q4 2022

Feb 14, 2023

SELL
$102.55 - $135.33 $1.7 Million - $2.25 Million
-16,619 Reduced 60.79%
10,720 $1.45 Million
Q3 2022

Nov 14, 2022

SELL
$95.28 - $116.93 $165 Million - $203 Million
-1,735,031 Reduced 98.45%
27,339 $2.72 Million
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $49.2 Million - $58 Million
476,258 Added 37.03%
1,762,370 $196 Million
Q1 2022

May 13, 2022

BUY
$93.1 - $112.54 $33.9 Million - $41 Million
364,372 Added 39.53%
1,286,112 $143 Million
Q4 2021

Feb 14, 2022

BUY
$95.88 - $117.08 $51.2 Million - $62.5 Million
533,804 Added 137.6%
921,740 $103 Million
Q3 2021

Nov 12, 2021

BUY
$84.42 - $106.62 $32.7 Million - $41.4 Million
387,936 New
387,936 $37.2 Million
Q1 2021

May 14, 2021

SELL
$67.06 - $75.82 $44.7 Million - $50.5 Million
-666,342 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$63.89 - $73.8 $37 Million - $42.8 Million
-579,693 Reduced 46.52%
666,342 $46.5 Million
Q3 2020

Nov 12, 2020

SELL
$63.69 - $70.22 $115 Million - $127 Million
-1,812,062 Reduced 59.25%
1,246,035 $86.5 Million
Q2 2020

Aug 12, 2020

SELL
$58.54 - $67.94 $48.4 Million - $56.2 Million
-826,889 Reduced 21.28%
3,058,097 $200 Million
Q1 2020

May 15, 2020

SELL
$49.46 - $64.78 $5.38 Million - $7.04 Million
-108,734 Reduced 2.72%
3,884,986 $234 Million
Q4 2019

Feb 13, 2020

SELL
$49.86 - $58.26 $9.03 Million - $10.5 Million
-181,011 Reduced 4.34%
3,993,720 $231 Million
Q3 2019

Nov 14, 2019

SELL
$47.54 - $53.43 $7.37 Million - $8.28 Million
-155,037 Reduced 3.58%
4,174,731 $216 Million
Q2 2019

Aug 14, 2019

SELL
$46.79 - $52.47 $92.6 Million - $104 Million
-1,978,797 Reduced 31.37%
4,329,768 $221 Million
Q1 2019

May 15, 2019

SELL
$46.36 - $52.63 $12.6 Million - $14.4 Million
-272,798 Reduced 4.15%
6,308,565 $330 Million
Q4 2018

Feb 14, 2019

BUY
$41.54 - $47.25 $176 Million - $200 Million
4,240,464 Added 181.15%
6,581,363 $303 Million
Q3 2018

Nov 14, 2018

SELL
$46.76 - $51.24 $27 Million - $29.6 Million
-578,151 Reduced 19.81%
2,340,899 $110 Million
Q2 2018

Aug 14, 2018

BUY
$44.29 - $50.42 $31.1 Million - $35.4 Million
701,210 Added 31.62%
2,919,050 $135 Million
Q1 2018

May 14, 2018

SELL
$48.49 - $58.14 $16.2 Million - $19.4 Million
-334,404 Reduced 13.1%
2,217,840 $109 Million
Q4 2017

Feb 09, 2018

BUY
$47.53 - $53.73 $93.8 Million - $106 Million
1,974,129 Added 341.48%
2,552,244 $137 Million
Q3 2017

Nov 14, 2017

BUY
$41.15 - $49.22 $23.8 Million - $28.5 Million
578,115
578,115 $27.8 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.